Reduction in pharmaceutical companies Nov Novartis cuts up to 130 jobs in Basel

Novartis has announced plans to cut up to 130 jobs at its facility in Basel, Switzerland, as part of a broader restructuring effort. The decision follows the planned shutdown of small-volume production of biologics at the site by the end of 2027. According to company communications, future operations will be handled by other biologics sites around the world. This move marks another step in Novartis' strategy to consolidate its global manufacturing capabilities. The closure is linked to expiring lease agreements at the Kleinbasel location. As a result, several activities currently based there, such as laboratories for biological cell banks, analytical testing procedures, and technical development work, will be relocated to the Novartis campus on the opposite side of the Rhine. The company emphasized that this relocation is part of its ongoing efforts to build a new center for biologics technology development on the campus, which would complement existing research facilities focused on biologics. Biologics are medications produced using living cells or biological processes. They differ from traditional chemically synthesized drugs and can help manage inflammatory conditions, regulate abnormal immune responses, or replace missing proteins to treat diseases. These complex treatments often require specialized manufacturing techniques and infrastructure, making them a key focus area for pharmaceutical companies like Novartis. In response to the announcement, the Swiss trade union Unia expressed concern over the continued reduction of production positions in the country. The union noted that this comes nine months after the last major job cuts in Stein, Aargau. Since 2018, Novartis has reportedly reduced nearly 3,000 positions in Switzerland. Unia called for the company to avoid layoffs altogether and instead find ways to retain employees at another location within the northwestern part of the country, rather than shifting production abroad. The company stated that it is committed to supporting affected employees through a range of measures, including a long-term social plan. All proposed changes remain subject to the information and consultation process, ensuring transparency with stakeholders. The firm has not yet disclosed specific details regarding alternative employment opportunities or potential redeployment options for impacted workers. Meanwhile, local authorities and community representatives have begun discussions about the implications of the job losses. Some have raised concerns about the impact on the regional economy and workforce stability. Others have pointed to the broader trend of corporate restructuring in the pharmaceutical sector, driven by cost-cutting pressures and evolving market demands. As the situation develops, further details about the exact number of roles affected, the timeline for implementation, and the availability of support programs for displaced workers are expected to emerge. Industry analysts suggest that such strategic shifts are increasingly common among multinational corporations seeking to optimize operational efficiency and align with global supply chain dynamics. However, the human element remains central, with unions and employee advocates continuing to push for more transparent communication and fair treatment during these transitions.